{
  "description": "Gold standard dataset for validating variant actionability assessment - SNPs and small indels only",
  "version": "2.1",
  "note": "Updated to only include somatic SNPs and small indels. Fusion, amplification, and germline variants removed. BRCA1 185delAG removed as it is a germline pathogenic variant, not a somatic tumor mutation.",
  "entries": [
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) with strong clinical evidence",
      "references": [
        "Chapman PB et al. N Engl J Med 2011",
        "Hauschild A et al. Lancet 2012"
      ]
    },
    {
      "gene": "EGFR",
      "variant": "L858R",
      "tumor_type": "Lung Adenocarcinoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved EGFR TKIs (erlotinib, gefitinib, afatinib, osimertinib)",
      "references": [
        "Rosell R et al. Lancet Oncol 2012"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G12C",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved KRAS G12C inhibitors (sotorasib, adagrasib)",
      "references": [
        "Skoulidis F et al. N Engl J Med 2021"
      ]
    },
    {
      "gene": "KIT",
      "variant": "D816V",
      "tumor_type": "Gastrointestinal Stromal Tumor",
      "expected_tier": "Tier I",
      "notes": "FDA-approved imatinib for KIT-mutant GIST",
      "references": [
        "Demetri GD et al. N Engl J Med 2002"
      ]
    },
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier II",
      "notes": "BRAF inhibitors show activity but are not first-line; combination therapy recommended",
      "references": [
        "Kopetz S et al. N Engl J Med 2019"
      ]
    },
    {
      "gene": "PIK3CA",
      "variant": "H1047R",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier II",
      "notes": "Alpelisib approved for PIK3CA-mutant, HR+/HER2- breast cancer",
      "references": [
        "Andre F et al. N Engl J Med 2019"
      ]
    },
    {
      "gene": "NRAS",
      "variant": "Q61K",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "No approved targeted therapies; MEK inhibitors show some activity in trials",
      "references": [
        "Ascierto PA et al. Lancet Oncol 2013"
      ]
    },
    {
      "gene": "TP53",
      "variant": "R175H",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier III",
      "notes": "No approved targeted therapies; prognostic but not predictive",
      "references": [
        "Olivier M et al. Cold Spring Harb Perspect Biol 2010"
      ]
    },
    {
      "gene": "IDH1",
      "variant": "R132H",
      "tumor_type": "Acute Myeloid Leukemia",
      "expected_tier": "Tier I",
      "notes": "FDA-approved ivosidenib for IDH1-mutant AML",
      "references": [
        "DiNardo CD et al. N Engl J Med 2018"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G12D",
      "tumor_type": "Pancreatic Cancer",
      "expected_tier": "Tier III",
      "notes": "No approved targeted therapies; KRAS G12D inhibitors in clinical trials",
      "references": [
        "Waters AM et al. Cold Spring Harb Perspect Med 2018"
      ]
    },
    {
      "gene": "EGFR",
      "variant": "T790M",
      "tumor_type": "Lung Adenocarcinoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved osimertinib for EGFR T790M-positive NSCLC after progression on first/second-gen TKIs",
      "references": [
        "Mok TS et al. N Engl J Med 2017"
      ]
    }
  ]
}
